300723 ApicHope Pharmaceutical
- 21.43
- -0.11-0.51%
ApicHope Pharmaceutical News
Poinsettia (300723.SZ) plans to pay 2.1 yuan for 10 shares to be deducted from interest on June 3
Poinsettia (300723.SZ) announced that the company's 2023 equity distribution plans: cash dividends for every 10 shares...
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Poinsettia (300723.SZ): A wholly-owned subsidiary, the first-class innovative drug APH01727 tablets were accepted for clinical trial registration
Gelonghui, May 14, 丨 Yipinhong (300723.SZ) announced that recently, the drug clinical trial application for APH01727 tablets, a class of innovative drugs independently developed by Guangzhou Yipinhong Pharmaceutical Co., Ltd. (hereinafter referred to as “Yipinhong Pharmaceutical”), a wholly-owned subsidiary of the company, was accepted by the China Drug Administration and received a “Notice of Acceptance”.
Poinsettia (300723) 2023 Report and 2024Q1 Quarterly Report Review Report: Innovative R&D continues to accelerate long-term development and is worth looking forward to
Incident The company released its 2023 annual report, achieving operating income of 2.503 billion yuan, a year-on-year increase of 9.79%; net profit to mother of 185 million yuan, a year-on-year decrease of 36.49%; net profit after deduction of 120 million yuan
Poinsettia (300723): Traditional business is steady, progressive and continuous development, AR882 R&D continues to embark on a new journey
Event: On April 26, 2024, the company announced 2023/2024Q1 results. In 2023, the company achieved revenue of 2.503 billion yuan (yoy +9.79%) and net profit of 185 million yuan to mother
A-share changes丨Yipinhong's wholly-owned subsidiary obtained an ocaxipine oral suspension registration certificate with an increase of more than 8%
Glonghui, May 6 | Poinsettia (300723.SZ) increased its increase in the afternoon. It now rose 8.18% to 24.6 yuan. The temporary transaction was 140 million yuan, and the latest market value was 11.17 billion yuan. Yipinhong announced this afternoon that its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical recently obtained a registration certificate for the oral suspension of oxazepine. Oxcarbazepine oral suspension is suitable for treating primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures. It is suitable for adults and children over 2 years of age, and can be used alone or in combination with other anticonvulsants.
Express News | Yipinhong: Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration for the oral suspension of oxacepine.
Poinsettia (300723): Short-term performance under pressure, R&D continues to advance
Incident: Yipinna released its 2023 annual report. In 2023, the company achieved operating revenue of 2.503 billion yuan, an increase of 9.79% over the previous year; realized net profit of 185 million yuan, a year-on-year decrease of 36.49%; achieved
Poinsettia (300723): Steady adjusted profits as AR882 R&D advances
Traditional business performance fluctuates, waiting for adjustments to begin a new stage of growth. The company announced 2023/1Q24 results on April 26:1) 2023 revenue/net profit/net profit deducted from non-net profit were 25.03/1.85, respectively
Poinsettia (300723.SZ) announced first-quarter results, net profit of 101 million yuan, a decrease of 9.53%
According to the Zhitong Finance App, Pinot (300723.SZ) released its report for the first quarter of 2024. The company's revenue was 623 million yuan, a year-on-year decrease of 13.01%. Net profit attributable to shareholders of listed companies was 101 million yuan, a year-on-year decrease of 9.53%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 98.094 million yuan, an increase of 5.16% over the previous year. Basic earnings per share were $0.2213.
Poinsettia (300723.SZ): The holding subsidiary signs a “Technical Service (Outsourcing) Contract” with Boji Pharmaceuticals
On April 7, Ge Longhui (300723.SZ) announced that its holding subsidiary Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. signed a “Technical Service (Outsourcing) Contract” with Boji Pharmaceutical Technology Co., Ltd. (“Boji Pharmaceutical”). The total contract amount is RMB 69.63 million (tax included. The total amount of the contract includes the project start-up cost of 2,587 million yuan in the “Early Launch Agreement for Class 1 New Chemical Drug AR882 Capsule Phase III Clinical Trials” signed by both parties in 2023). The contract agreed that Guangzhou Ruianbo commissioned Boji Pharmaceutical to launch “AR882 capsules” to treat primary pain
Poinsettia (300723.SZ): As of March 29, 2024, the total number of shareholders of the company was 13,159
Gelonghui, April 1, 丨 Pinus (300723.SZ) said on the investor interactive platform that as of March 29, 2024, the total number of shareholders of the company was 13,159.
Express News | Sinopharm Holdings visited Yipinhong for visits and exchanges
Poinsettia (300723): Innovative drugs for gout that are deeply involved in the field of pediatric and chronic disease medication can be expected in the future
Focusing on the field of medicine for children and chronic diseases, the company is in a stage of rapid development. Yipinna was founded in 2002 and listed on the Shenzhen Stock Exchange in 2017. The company focuses on the fields of children's medicine, chronic medicine and biological vaccines. The product categories include chemical drugs (
Poinsettia (300723): Fenghua Zheng Mao went to the next level
A domestic comprehensive pharmaceutical company that has successfully transformed, innovated and started again; “bought” for the first time, Yipinhong is an innovative biomedical enterprise integrating drug R&D, production, and sales. It mainly focuses on the fields of children's medicine, chronic medicine and biological vaccines. presently
Express News | Poinsettia: A wholly-owned subsidiary obtained a registration certificate for amlodipine benzenesulfonate dry suspension
Poinsettia (300723.SZ): As of January 19, 2024, the total number of shareholders of the company was 9,753
On January 22, Ge Longhui (300723.SZ) said on the investor interactive platform that as of January 19, 2024, the total number of shareholders of the company was 9,753.
Poinsettia (300723.SZ): As of January 10, 2024, the total number of shareholders of the company was 9874
On January 12, Ge Longhui (300723.SZ) said on the investor interactive platform that as of January 10, 2024, the total number of shareholders of the company was 9,874.
Poinsettia (300723.SZ): Pipeline product recombinant protein nanoparticle influenza vaccine is currently in preclinical research
Gelonghui, January 8, 丨 Yipinhong (300723.SZ) said on the investor interactive platform that the company is a pharmaceutical innovation enterprise focusing on the field of children's medicine and chronic disease medicine; the company's pipeline product recombinant protein nanoparticle influenza vaccine is currently still in the pre-clinical research stage.
Poinsettia (300723.SZ): Currently, the company has more than 100 research projects
Glonghui, December 21丨An investor asked Poinsette (300723.SZ) on the investor interactive platform, “Does your company have a research and development office in Mabalosawe?” The company replied that, relying on the three innovative technology research and development platforms for pediatric medicine, chronic disease drugs, and biogenetic vaccines, the company has built a product pipeline with pediatric drug products, chronic disease drug products as the core, and biogenetic vaccine products as the core, and biogenetic vaccine products as the extension, covering a variety of common diseases with urgent clinical demand. Currently, the company is developing more than 100 projects, including 31 pediatric drugs and 41 chronic disease drugs. For the specific R&D situation, please pay attention to the company's regular report
Analysis
Price Target
No Data
